Gilead Sciences (GILD) EBIAT (2016 - 2025)
Historic EBIAT for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.
- Gilead Sciences' EBIAT rose 14357.54% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 billion, marking a year-over-year increase of 633650.79%. This contributed to the annual value of $480.0 million for FY2024, which is 9152.69% down from last year.
- Per Gilead Sciences' latest filing, its EBIAT stood at $3.1 billion for Q3 2025, which was up 14357.54% from $2.0 billion recorded in Q2 2025.
- Gilead Sciences' EBIAT's 5-year high stood at $3.1 billion during Q3 2025, with a 5-year trough of -$4.2 billion in Q1 2024.
- Its 5-year average for EBIAT is $1.2 billion, with a median of $1.5 billion in 2021.
- In the last 5 years, Gilead Sciences' EBIAT skyrocketed by 521578.95% in 2023 and then crashed by 51287.13% in 2024.
- Quarter analysis of 5 years shows Gilead Sciences' EBIAT stood at $382.0 million in 2021, then soared by 329.32% to $1.6 billion in 2022, then fell by 12.87% to $1.4 billion in 2023, then increased by 24.77% to $1.8 billion in 2024, then skyrocketed by 71.17% to $3.1 billion in 2025.
- Its EBIAT was $3.1 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.3 billion in Q1 2025.